Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

This study has been completed.
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research Identifier:
First received: August 14, 2007
Last updated: September 28, 2015
Last verified: September 2015